S4257 Portal Vein Thrombosis in the Setting of MTHFR Mutation Despite Full Anticoagulation on Apixaban (Eliquis)

Harman Sawhney,Dhanush Hoskere,Andrew Shehata,George Koutras,Kovil Ramasamy,Vivek Gumaste,Michael Duhaney
DOI: https://doi.org/10.14309/01.ajg.0001046396.00531.b8
2024-10-26
The American Journal of Gastroenterology
Abstract:Methylenetetrahydrofolate Reductase (MTHFR) mutation increases the incidence of thrombus formation throughout the body. MTHFR gene mutations are rare autosomal recessive disorders associated with developmental delay, ocular abnormalities and thromboembolic disease. Here, we present a patient with Liver Cirrhosis and MTFHR mutation who had been anticoagulated with therapeutic Apixaban (Eliquis) but developed a splenic artery and portal vein thrombosis complicated by ascites.
gastroenterology & hepatology
What problem does this paper attempt to address?